Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03392246
Title A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Massachusetts General Hospital Boston Massachusetts 02214 United States Details
Beth Israel Deaconess Medical Center Boston Massachusetts 02215 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
Duke University Durham North Carolina 27710 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field